Fate Therapeutics
FATE
146 hedge funds and large institutions have $70.9M invested in Fate Therapeutics in 2025 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 31 increasing their positions, 54 reducing their positions, and 17 closing their positions.
24% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 17
2% more funds holding
Funds holding: 143 → 146 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.34% less ownership
Funds ownership: 69.87% → 62.54% (-7.3%)
30% less capital invested
Capital invested by funds: $102M → $70.9M (-$30.6M)
43% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 54
43% less call options, than puts
Call options by funds: $70K | Put options by funds: $122K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.83M |
| 2 |
Renaissance Technologies
New York
|
+$1.32M |
| 3 |
Two Sigma Investments
New York
|
+$1M |
| 4 |
Two Sigma Advisers
New York
|
+$774K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$660K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wilshire Advisors
Santa Monica,
California
|
-$10.7M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.03M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$949K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$841K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$621K |
FATE Hedge Fund Activity: Q4 2025 in Review
146 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2025, worth a combined $70.9M — down 30% from $102M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new FATE positions and 17 closed out — a net gain of 4 holders — while 31 added to existing stakes and 54 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $1.83M. The largest seller was Wilshire Advisors, exiting entirely with an estimated $10.7M sold.
- 146 institutional investors held Fate Therapeutics (FATE) as of Q4 2025, up from 143 in Q3 2025.
- Funds reported $70.9M of Fate Therapeutics stock for Q4 2025, down 30% quarter-over-quarter.
- 21 funds opened new Fate Therapeutics positions in Q4 2025 and 17 closed out, a net change of +4 holders.
- The largest Fate Therapeutics buyer in Q4 2025 was Point72 Asset Management, an estimated $1.83M added.
- The largest Fate Therapeutics seller in Q4 2025 was Wilshire Advisors, an estimated $10.7M sold.
Based on aggregated 13F filings for Q4 2025.